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Abstract 
Methotrexate (MTX) is an antimetabolite of the normal folic acid produced by human and animal bodies. MTX 
antagonizes Folic Acid which is vital for purine and many vital amino acids. Treatment with MTX has been 
widespread all over the world recently. Physicians usually prescribe folic acid together or following treatment 
with MTX. Some patients minimize the importance of having folic acid with MTX or after it regarding it as a not 
essential drug as MTX. From here it comes, the value of this research to clarify the important role of folic acid in 
minimizing the side effects of MTX. In fact this effect applies on most systems in the human and animal bodies; 
however, authors prefer to focus on the neurological aspects as references are somewhat scarce especially in the 
veterinary aspect and found some behavioral changes which coincide with brain histopathological findings.   
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1. Introduction 
Methotrexate is an antimetabolite and antifolate drug, has been spread in the last years as a cure for large list of 
diseases in both human and veterinary fields. Therefore, it is important to study its effect on variant systems and 
organs. From these organs, the nervous system is important to study as its review regarding this drug is 
somewhat rare in comparison to others. 
Methotrexate abbreviated (MTX) and formerly known as amethopterin, is an antimetabolite and 
antifolate drug. It is used in the treatment of cancer, autoimmune diseases, ectopic pregnancy (Alshimmiri et al., 
2003), and for the induction of medical abortions (Vinet, 2013). In addition, it is used for treatment of psoriasis 
(Kozub and Simaljakova, 2011). Methotrexate has been spread in the last years as a cure for large list of diseases 
in both human and veterinary fields (especially for pets in case of rheumatoid arthritis (Rheumatrex®) USP. 
Medical uses of methotrexate: 
Chemotherapy 
Methotrexate (MTX) was originally developed and continues to be used for chemotherapy either alone or in 
combination with other agents. It is effective for the treatment of a number of cancers including: lung, head and 
neck cancers, leukemia, lymphoma, osteosarcoma, bladder, and trophoblastic neoplasms (Bayram et al. 2005). 
Autoimmune disorders 
It is used as a treatment for some autoimmune diseases, including rheumatoid arthritis, Juvenile dermatomyositis, 
psoriasis, lupus, sarcoidosis, and many forms of vasculitis. Although methotrexate was originally designed as a 
chemotherapy drug (in high doses), in low doses it is a generally safe and well tolerated drug in the treatment of 
certain autoimmune diseases (Cronstein, 2005). 
Because of its effectiveness, low-dose methotrexate is now first-line therapy for the treatment of rheumatoid 
arthritis. Therefore, methotrexate for autoimmune diseases is taken in lower doses than it is for cancer. Side 
effects such as hair loss, nausea, headaches, and skin pigmentation are still common. 
Folic Acid: 
Dihydrofolate reductase (DHFR) is a key enzyme for the biosynthesis of purines, thymidylate, and a number of 
amino acids. It has strategic location in metabolism has also made it a target for anticancer drugs (Zhang et al. 
2004). 
MTX acts by inhibition of folic acid synthesis, this is why giving its antagonist (FA), could be the optimum 
related treatment along with MTX for gaining a minimum side effects. 
This experiment was designed to clarify the role of oxidative stress of MTX and the possible protective effect of 
its antagonist (FA) on the neurological tissue using histopathological examinations. 
 
2. Materials and Methods 
15 female Albino rats of 200-250 gm were obtained from the house of animals, Faculty of Veterinary Medicine, 
University of Mosul. Rats for this experiment divided into 4 groups randomly. Group 1 represents control 
injected with distilled water 0.6 ml/ rat every week for 4 weeks. Group 2 were given folic acid 1mg/ rat orally by 
drenching every week for 4 weeks too. Group 3 were injected with MTX intramuscularly 20mg/ kg b.wt. every 
week for the same period. Group 4 were given folic acid and injected with MTX concomitantly with the same 
previous doses, periods, and routes of administration. Range of rat weights was as follows: 
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Weight (gm) Rat number 
240 1 
245 2 
215 3 
200 4 
235 5 
195 6 
200 7 
215 8 
175 9 
205 10 
195 11 
185 12 
175 13 
205 14 
230 15 
Methotrexate solution (50mg/5ml) (1Flakon) ® is available commercially. For intramuscular injection 
dose of 0.4 mg/kg for rats was administered by (Fan et al., 2009). For our study, it is preferred to use the dose 20 
mg/ kg b.wt. based on a previous related study (Soliman, 2009). Folic acid (FA) was administered orally by 
needle gavage at 1 mg/ rat once weekly (Fan et al., 2009). 
After 4 weeks, rats were sacrificed by merciful killing. Brain and allied Central Nervous System 
organs were fixed with 10% neutral buffered formalin fixative for routine histopathological sections.  
 
3. Results 
Animal behavior: 
Rats treated with MTX were dull as revealed in the following photos and suffered from alopecia 
 
Photos show a dull rat, treated with MTX (Left), another rat suffered from alopecia at face region (Right). 
This group treated with MTX alone. 
 
Macroscopic lesions of the brain: 
The gross appearance of the brain in the treated group with methotrexate was suffering from severe 
congestion in comparison to the control group which is similar to the group treated with MTX. The brain 
of the treated rats with both MTX and FA revealed a better improvement in comparison to the treated 
group. 
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1. Control group 
 
 
2. Treated with MTX 
 
 
3. Treated with MTX and FA 
 
Photos reveal the severe macroscopic congestion of the brain of animals treated with MTX (2) in 
comparison to control animals (1) and the ameliorative effect of folic acid treated animals (3). 
 
Microscopic lesions of the brain 
 
Photos reveal the congestion of the brain (Left 142X) and the ameliorative effect of folic acid on brain to 
be as a mild congestion (Right 43X). 
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Photos (420X) Cross section of a dead neuron surrounded by microglial cells that phagocytize the cell 
debris (neurophagia) ( (left) (420 X) represents a section of brain which reveals the congestion and the 
beginning of a recent thrombus with areas of vasogenic edema with some spongy change (right) 
 
Photo 105X shows the presence of abscess in a region of the brain represented by pus material and 
cellular debris surrounded by a region of hyperemia and spongiosis.  
 
4. Discussion 
MTX acts by inhibition of Folic acid (FA), This is done by inhibition of cellular synthesis of purines, 
pyrimidines and methionine, methotrexate polyglutamate; RFC1, reduced folate carrier 1; DHFR, dihydrofolate 
reductase;THF, tetrahydrofolate; TS, thymidylate synthase; MTHFR, methylene tetrahydrofolate reductase; 
FPGS, folyl polyglutamate synthase;AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AICART’ASE, 
AICAR transformylase (Cronstein, 2005). 
This study was in agreement with some other studies in which their results indicate that high-dose 
MTX is related with modest toxicity and a radiographic response proportion (74%) was equivalent to more toxic 
regimens (Batchelor, et. al., 2003). Another study included a patient developed probable MTX-induced 
leukoencephalopathy, the symptoms included headache and confusion (Gowan, et al., 2002). 
However, it was found that there are some studies showed central nervous system (CNS) toxicity from 
low-dose methotrexate (MTX) has been reported with symptoms consist mainly of dizziness and headache. This 
study reviewed the records of 25 successive patients treated with low-dose MTX, and found 5 who had 
spontaneously reported unpleasant cranial sensations (Wernick and Smith, 1989). 
Interestingly, cases in which abscess in cerebrum was found in treated group with MTX was in 
agreement with animal behavior of depression and dullness. This result is scientifically reported (Zachary and 
McGavin, 2006). 
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